Add Giardiasis

[caufieldjh]

No description provided.

[claude]

Claude finished @caufieldjh's task in 4m 53s —— View job

---

PR Review: Add Giardiasis

• Gather context and read changed files
• Review biological and clinical validity
• Review conformance with guidelines
• Review completeness
• Post final review

---

Overall Assessment

This is a high-quality, comprehensive entry for Giardiasis. The biological and clinical content is accurate, well-structured, and well-evidenced. The pathophysiology is notably thorough, with a well-decomposed causal chain from cyst ingestion through to clinical sequelae. A few issues are flagged below, but none are blockers.

---

Biological and Clinical Validity ✅

The entry is biologically sound:

• The pathophysiology cascade (cyst ingestion → trophozoite colonization → assemblage-specific epithelial injury → tight junction disruption + apoptosis → barrier dysfunction → malabsorption) is accurate and well-cited.
• Claudin-1 downregulation (PMID:16935925) and PKC α/β II dephosphorylation under hypoxia (PMID:35868574) are legitimate and appropriately specific mechanistic claims.
• Assemblage-dependent pathogenicity variation is correctly modeled using in vitro data (PMID:22924932 — IN_VITRO ✓).
• Phenotype frequencies are clinically appropriate (diarrhea: VERY_FREQUENT; flatulence, abdominal pain, bloating: FREQUENT; steatorrhea/malabsorption/weight loss: OCCASIONAL).
• Treatments are accurate: tinidazole single-dose first line, metronidazole alternative, paromomycin for pregnancy, nitazoxanide as alternative.
• Post-infectious IBS and functional dyspepsia are recognized sequelae, well-cited (DOI:10.1136/gutjnl-2023-331835).
• Pediatric growth delay and cognitive impairment are clinically established and correctly qualified as context-dependent (malnutrition + LMIC settings).

All checked snippets match their source abstracts exactly.

---

Issues

1. IBS Phenotype Term Uses MONDO Instead of HP (Important)

kb/disorders/Giardiasis.yaml lines 754–757:

phenotype_term:
  preferred_term: irritable bowel syndrome
  term:
    id: MONDO:0005052
    label: irritable bowel syndrome

phenotype_term.term should use an HP ontology term, not MONDO. MONDO terms are used for disease_term and differential_diagnoses. Please look up the appropriate HP term with:

uv run runoak -i sqlite:obo:hp search "irritable bowel syndrome"

If no suitable HP term exists, consider omitting the term block and using only preferred_term, or modeling this as a complication in a comorbidities entry rather than a phenotypes entry.

Fix this →

2. Nitazoxanide Treatment Missing therapeutic_agent CHEBI Term (Suggestion)

Lines 842–854: the nitazoxanide entry lacks a therapeutic_agent block, unlike the other treatment entries (tinidazole/metronidazole, paromomycin). For consistency:

treatment_term:
  preferred_term: pharmacotherapy
  term:
    id: MAXO:0000058
    label: pharmacotherapy
  therapeutic_agent:
  - preferred_term: nitazoxanide
    term:
      id: CHEBI:63082
      label: nitazoxanide

Fix this →

3. evidence_source: OTHER for Epidemiological/Clinical Reviews (Suggestion)

Many evidence items that cite epidemiological or clinical review papers use evidence_source: OTHER. Per CLAUDE.md, OTHER is for evidence types that don't cleanly fit. Several of these references present or synthesize human clinical data and should be HUMAN_CLINICAL:

• PMID:41280732 — epidemiological outbreak review (waterborne outbreaks in Europe), used in transmission and epidemiology sections
• PMID:37764167 — clinical review of cryptosporidiosis/giardiasis in children
• PMID:14501998 — clinical review (Curr Opin Infect Dis, 2003)
• PMID:17070814 — clinical review (Int J Parasitol, 2007)

PMID:30020611 (StatPearls textbook chapter) is a reasonable use of OTHER since it is a textbook rather than primary research.

4. Orphaned Reference Cache Files (Minor)

Five cache files were added but are not cited in Giardiasis.yaml:

File	Content
DOI_10.3390_microorganisms11092323.md	Duplicate of PMID:37764167 (same paper)
DOI_10.1007_s11686-024-00828-9.md	PCR/metronidazole resistance in Giardia (content unavailable)
DOI_10.1080_19490976.2024.2412676.md	Giardia-induced microbiota dysbiosis/mucin glycosylation (content unavailable)
DOI_10.3390_ijms25168627.md	Giardia, immune system, and metabolic disorders
DOI_10.1007_s40475-024-00314-2.md	Stunting/cognitive deficits review (content unavailable)

These appear to be candidate references that were fetched but not ultimately used. They are harmless, but DOI_10.3390_microorganisms11092323.md could be removed since it is a duplicate of an already-cached PMID. The others could enhance currently empty sections (biochemical, future comorbidities) or strengthen existing nodes.

5. GEO Reference Prefix Case Inconsistency (Minor)

datasets[*].accession uses lowercase geo: (e.g., geo:GSE36490 at line 1075) while datasets[*].evidence[*].reference uses uppercase GEO: (e.g., GEO:GSE36490 at line 1093). These should be consistent — check which form the schema validator expects.

---

Completeness

• histopathology: [], biochemical: [], genetic: [] — All three are empty.
  • Histopathology in giardiasis includes villous blunting and crypt hyperplasia on duodenal biopsy, which is an established finding (though not routinely needed for diagnosis). Adding these would improve the entry.
  • Biochemical: D-xylose absorption, stool fat, or vitamin B12 levels in malabsorptive disease are relevant but not critical.
  • Genetic: Correct that this is empty — giardiasis has no known host genetic predisposition gene entries.
• comorbidities section is absent — consider adding immunodeficiency states (hypogammaglobulinemia, CVID, HIV) as conditions that predispose to severe/recurrent giardiasis.
• The entry is otherwise very complete with 11 phenotype entries, 8+ pathophysiology nodes, 3 datasets, 2 clinical trials, multiple treatment entries, and differential diagnoses.

---